Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray PR Newswire LONDON, December 19, 2013 LONDON, December 19, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Wednesday, December 18, 2013, the US equity market finished the day on a higher note. The S&P 500 closed the day 1.66% higher at 1,810.65; the Dow Jones Industrial Average finished 1.84% higher at 16,167.97; and the NASDAQ Composite ended 1.15% higher at 4,070.06. The S&P 500 Health Care Sector Index ended the day at 634.55, up 2.40%; and the same has advanced 2.17% in the previous three trading sessions and 5.66% in the last three months, outperforming the S&P 500, which has advanced 1.99% and 4.93%, during the respective periods. The major movers in the sector included ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Chelsea Therapeutics International. Ltd (NASDAQ: CHTP), Antares Pharma Inc. (NASDAQ: ATRS), and Accuray Inc. (NASDAQ: ARAY). AAAResearchReports.com free coverage on ZIOP, CHTP, ATRS, and ARAY is available upon registration at: http://www.aaaresearchreports.com/register/ On Wednesday, shares in ZIOPHARM Oncology Inc. advanced to end the day at $3.93, up 2.88% from the previous day's closing price of $3.82. The company's shares oscillated between $3.74 and $4.01 during the trading session. A total of 1.03 million shares were traded, which is below the daily average volume of 1.33 million. The company's shares have gained 9.47% in the last one month and 19.82% in the previous three months, outperforming the S&P 500, which has gained 1.07% and 4.93%, during the respective periods. Furthermore, ZIOPHARM Oncology Inc.'s stock is trading above its 50-day and 200-day moving averages of $3.89 and $3.03, respectively. Download free technical research on ZIOP by signing up at: http://www.AAAResearchReports.com/ZIOP121913.pdf Shares in Chelsea Therapeutics Intl. Ltd surged on Wednesday, hitting a new 52-week high of $4.00. The company's closed the day at $3.97, up 3.66% from the previous day's closing price of $3.83. A total of 1.90 million shares were traded, which is above the daily average volume of 1.18 million. The company's shares have gained 20.30% in the last one month and 26.03% in the previous three months, outperforming the S&P 500, which has gained 1.07% and 4.93% during the respective periods. Moreover, Chelsea Therapeutics Intl. Ltd's stock is trading above its 50-day and 200-day moving averages of $3.26 and $2.62, respectively. Register now and get access to free analysis on CHTP at: http://www.AAAResearchReports.com/CHTP121913.pdf On Wednesday, Antares Pharma Inc.'s stock surged, as the broader market posted gains. The company's shares finished the day 3.80% higher at $4.23, after fluctuating between $4.05 and $4.31. A total of 1.82 million shares were traded, which is below the daily average volume of 1.84 million. The company's shares have gained 7.09% in the previous three trading sessions and 12.50% in the last one month, outperforming the S&P 500, which has advanced 1.99% and 1.07%, during the respective periods. Further, Antares Pharma Inc.'s stock is trading above its 50-day and 200-day moving averages of $4.01 and $4.05, respectively. Sign up and read our complimentary report on ATRS at: http://www.AAAResearchReports.com/ATRS121913.pdf Accuray Inc.'s stock vacillated between $8.30 and $8.57 before hitting a new 52-week high of $8.57. The company shares ended the Wednesday's session flat at the previous day's closing price of $8.41. A total of 1.10 million shares were traded, which is above the daily average volume of 1.01 million. The company's shares have gained 4.60% in the previous three trading sessions and 24.13% in the last three months, outperforming the S&P 500, which has advanced 1.99% and 4.93%, during the respective periods. Additionally, Accuray Inc.'s stock is trading above its 50-day and 200-day moving averages of $7.64 and $6.12, respectively. The free report on ARAY can be downloaded by signing up now at: http://www.AAAResearchReports.com/ARAY121913.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org
IBM No Longer Sees Delivering 'at Least $20 Operating EPS' in 2015
Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray
Press spacebar to pause and continue. Press esc to stop.